newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450

  • AEON Biopharma submitted an Investigational New Drug application to the FDA for a comparative pharmacodynamic study of ABP-450 using compound muscle action potential measurements.
  • The IND submission follows a recent FDA Type 2b meeting that provided clarity on the development pathway for ABP-450 as a biosimilar to BOTOX®.
  • The planned CMAP study aims to generate objective evidence comparing the neuromuscular activity of ABP-450 and BOTOX® to detect potential differences.
  • Study initiation for the CMAP trial is expected in the first quarter of 2027.
  • AEON intends to use a totality-of-evidence strategy that may support a biosimilar BLA without a standalone comparative clinical efficacy study.
  • The development approach emphasizes sensitive analytical & pharmacodynamic assessments to address residual uncertainty regarding biosimilarity.
  • ABP-450 is the same botulinum toxin complex currently marketed by Evolus as Jeuveau® for cosmetic indications.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, & other international territories.
  • The CMAP study is designed to bridge comparative analytical evidence with clinical pharmacology data to strengthen the scientific foundation for biosimilarity.
  • FDA draft guidance from October 2025 suggests comparative analytical methods may be more sensitive than comparative efficacy studies for detecting product differences.
Company
AEON Biopharma Inc
Keywords
NYSE:AEON, AEON Biopharma Inc